SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a massive $27 billion AI infrastructure deal with Meta, which significantly bolsters the company's long-term contracted backlog. While the community is debating the impact of a new $3.75 billion convertible debt offering intended to fund this rapid expansion, many remain bullish on the stock's long-term potential due to sustained backing from industry giants like NVIDIA and Microsoft.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing heightened volatility and trading volume as investors position themselves ahead of the upcoming fourth-quarter earnings release and monitor key regulatory milestones. The community is actively debating the company's long-term potential as a provider of nuclear energy for AI data centers versus concerns regarding its pre-revenue status, recent insider selling, and the broader macro-driven rotation out of high-beta speculative equities.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is drawing significant attention following its Nasdaq IPO and volatile market debut, with investors debating the growth potential of its drone autonomy software currently deployed in combat zones.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is experiencing heightened volatility and investor attention following positive Phase 3 clinical data for its Retevmo therapy and reports that the company has built significant inventory ahead of a potential April FDA decision on its oral obesity pill. Meanwhile, the broader community remains focused on the intense competitive landscape between LLY and Novo Nordisk, closely monitoring pricing strategies, new drug delivery formats, and ongoing regulatory scrutiny regarding the compounded weight-loss drug market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to a significant insider purchase of 550,458 shares and a completed capital raise, which the community views as a major vote of confidence in the company's clinical trajectory. Sentiment is currently divided between long-term holders focusing on upcoming Phase 3 milestones and BLA filings, and skeptics who remain concerned about the impact of dilution on shareholder value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing active community discussion as traders monitor potential buyout interest and growth prospects for its MS therapy, BRIUMVI, ahead of the company's upcoming earnings call. Investors are focused on the firm's revenue trajectory, recent long-term clinical data, and the potential impact of share repurchases on stock performance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and heavy trading volume ahead of the upcoming Optical Fiber Communications Conference (OFC), as market participants speculate on potential major partnership announcements and purchase orders. Community sentiment remains polarized between long-term investors tracking institutional accumulation and technical alignment with hyperscale AI hardware, and skeptics voicing concerns over persistent pre-revenue status and reliance on strategic collaborations.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to a preliminary update from its Phase 3 FLAMINGO-01 trial, which revealed an exceptionally low recurrence rate of less than 1% per year in the open-label arm. Investors are heavily discussing the significance of these consistent long-term results, with the community actively speculating on upcoming abstract titles for the AACR annual meeting and potential strategic partnerships or buyouts.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors monitor the appointment of a new CFO and anticipate the potential announcement of a major hyperscaler tenant. While some community members remain skeptical of management's communication and deal timelines, others are optimistic that the company's behind-the-meter energy model will drive significant long-term growth as infrastructure demand for AI continues to rise.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to a significant settlement regarding patent litigation, a move that removes a long-standing legal overhang and shifts market focus toward the company's robust oncology pipeline and combination vaccine potential. Community discussion is heavily focused on the stock's high short interest and the potential for a major strategic partnership or buyout to accelerate future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tilray Brands, Inc. faces a regulatory reckoning: regain Nasdaq’s minimum bid price requirements soon or possibly get delisted from the exchange.&nbsp;The retail trading community on Stocktwits believes the cannabis and beer company will soon overcome this hurdle.Leamington, Canada-based Tilray received a non-compliance notice from Nasdaq on Tuesday after its stock failed to maintain the exchange’s $1 minimum closing bid price requirement for 30 consecutive business days.Shares of Tilray have lost more than half their value this year, as cannabis-linked stocks continue to struggle amid stalled federal legalization efforts.The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.If the company fails, it may transfer to the Nasdaq Capital Market for another 180-day extension — provided it meets other listing requirements and notifies Nasdaq of its plan to fix the issue, possibly through a reverse stock split.&nbsp;If Nasdaq still determines the company cannot regain compliance, its stock will face delisting.On Stocktwits, sentiment for Tilray ended on a slightly higher ‘bullish’ level on Wednesday amid a 45% jump in message volume.<figure class="image"><img style="aspect-ratio:1318/302;" src="https://news.stocktwits-cdn.com/TLRY_sentiment_and_message_volume_as_of_Macrh_26_png_785b929906.webp" alt="TLRY sentiment and message volume as of Macrh 26.png" width="1318" height="302"><figcaption>TLRY sentiment and message volume as of Macrh 26. | source: Stocktwits</figcaption></figure>One user expressed hopes of Nasdaq being lenient with its process and said there were “zero” delisting fears because, with the extension, Tilray has until April 2026 to regain compliance.<stembedurl>https://stocktwits.com/Finance88/message/609341203</stembedurl>Another user said the company is “vertically scaled to be dominant from flower to drinks to pharma,” pointing to its products being available on the multinational supermarket chain Whole Foods, which is owned by Amazon.com.<stembedurl>https://stocktwits.com/Heb1972/message/609362664</stembedurl>Several retail investors on Stocktwits hope Tilray does not resort to a reverse stock split.<stembedurl>https://stocktwits.com/Rs1015/message/609258289</stembedurl>In January, Tilray’s stock was dealt a blow after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slides-after-q2-2025-results/chGWAd2RZD">reported</a> disappointing quarterly results and projected a $20 million revenue blow for 2025 from cutting back on certain alcohol beverage brands.Meanwhile, the company said Wednesday that the Massachusetts Superior Court dismissed a lawsuit filed by a shareholder against the company and its subsidiary Hexo.The plaintiff claimed Tilray failed to inform shareholders about Hexo’s corporate actions in late 2022 and its 2023 acquisition, allegedly causing financial losses. He sought nearly $8 million in damages.&nbsp;According to Koyfin data, short interest on Tilray has shot up from 12.7% at the start of the year to 17.3% as of the last week.The stock trades at a significant 180% discount to Wall Street’s average price target of $1.83. Out of 13 analysts covering it, nine rate it ‘hold’ and four ‘buy.’For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of a Canadian pharmaceutical and cannabis company, Tilray, is seen on a smartphone and a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Tilray Retail Bulls See Nasdaq Compliance On The Horizon, Shareholder Lawsuit Victory Adds Cheer

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.

Equity

The company has 180 calendar days to meet Nasdaq's minimum bid price rule. Its stock must close at or above $1.00 per share for at least 10 consecutive business days before Sept. 21.


Shares of Tilray Brands tumbled over 12% on Thursday, hitting their lowest point since Dec. 20, as the cannabis and beer company reported disappointing fiscal second-quarter (Q2) results and projected a $20 million revenue blow for 2025.The company posted a Q2 net loss of $85.3 million, nearly doubling its year-ago loss of $46.2 million.&nbsp;Cannabis net revenue fell slightly to $66 million from $67 million in the prior year.&nbsp;While overall Q2 revenue rose 8.8% year-over-year to $211 million, it missed Wall Street’s estimate of $216.33 million.Tilray also launched “Project 420,” a $25 million initiative to streamline its beverage business.&nbsp;The plan involves cutting back on certain alcohol beverage brands,&nbsp;which will contribute to the $20 million anticipated revenue impact for fiscal 2025.&nbsp;The company cited prioritizing key products and discontinuing underperforming stock keeping units (SKUs) as reasons for the dip.&nbsp;For the six months ended Nov. 30, 2024, the company reported a $6.0 million reduction in net sales, driven by the prioritization of certain products in key markets.&nbsp;An additional $2.0 million decline resulted from the decision to discontinue specific SKUs due to market conditions, Tilray said.However,&nbsp;the firm expects the move to be offset by innovation in new beverage categories and brand extensions over the next 18 months.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TLRY_sentiment_and_message_volume_Jan_10_premarket_d6cc8d488d.png" alt="TLRY sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>TLRY sentiment and message volume Jan 10 as of 11 am ET | source: Stocktwits</figcaption></figure>Despite the underwhelming financial performance, retail investors on Stocktwits remained surprisingly bullish.&nbsp;Many speculated on the possibility of a reverse stock split and expressed optimism about management’s potential for a turnaround.&nbsp;<stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/PerCentInvestments/message/599550073</stembedurl><stembedurl>https://stocktwits.com/Finer1m2/message/599547388</stembedurl><stembedurl>https://stocktwits.com/Big_Fish_76/message/599462909</stembedurl>There was also some solace in Tilray breaking even on an adjusted basis, outperforming analysts’ expectations of a $0.03 per share loss.<a href="https://stocktwits.com/symbol/TLRY">Tilray's stock</a> lost 34% in 2024.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tilray Stock Dips To 4-Week Low On $20M Revenue Blow Projection For 2025, But Retail’s Still Riding High

Tilray launched “Project 420,” a $25 million initiative to streamline its beverage business that involves cutting back on certain alcohol brands.

AMC Entertainment Holdings (AMC) is set to unveil its Q2 earnings after market close on Friday. Neither Wall Street nor the stock’s retail investor base seems optimistic about the results.The company has endured a challenging year, impacted by the 2023 actors' and writers' strikes, which significantly curtailed movie releases.Consequently, AMC projected a year-over-year revenue decline of 23.50% for Q2. However, the company also hinted at improved profitability, forecasting a narrower-than-expected loss per share.On Stocktwits, retail sentiment for the stock has improved since it released preliminary numbers, but it remains bearish (44/100) hours before earnings results are due.<figure class="image"><a href="https://stocktwits.com/symbol/AMC"><img style="aspect-ratio:1324/1018;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/AMC_sentiment_graph_showing_improvement_from_Jul_22_to_Aug_2_0b99fb2c84.png" alt="AMC sentiment graph showing improvement from Jul 22 to Aug 2.png" width="1324" height="1018"></a><figcaption>AMC sentiment graph showing improvement from Jul 22 to Aug 2</figcaption></figure>The recent smashing success of films like "Deadpool &amp; Wolverine" has boosted attendance, and the company's recent debt restructuring deal has injected a degree of optimism.However, AMC, a known “meme stock” that has experienced a great deal of volatility this year alongside GameStop, has lost nearly 19% of its valuation in 2024.The decision to release Q2 earnings after market close on a Friday adds an element of uncertainty, and could amplify market reactions due to speculation over the weekend. Retail investors may already be hinting at signs of things to come.

AMC Entertainment expects a 23.50% year-over-year fall in its revenue at $1.03 billion

AMC’s Retail Sentiment Bearish As Q2 Report Nears: Movie Magic Fading?

On Stocktwits, retail sentiment for the stock has improved since it released preliminary numbers, but remains bearish hours before earnings results are due.

AMC Entertainment Holdings on Wednesday announced preliminary earnings for the second quarter of 2024. The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion. As for its earnings, it expected a net loss of $32.80 million (down from $8.60 million in net income a year ago). Shares of the firm fell nearly 8% following the announcement while retail sentiment continued to trend in extremely bearish territory (18/100) supported by high message volumes.<figure class="image"><img style="aspect-ratio:788/224;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_1_32_10_PM_652954d4bf.png" alt="Retail sentiment trends in extremely bearish territory for AMC Entertainment" width="788" height="224"><figcaption>Retail sentiment trends in extremely bearish territory for AMC Entertainment</figcaption></figure>AMC has attributed the weakness to the prolonged actors’ and writers' strikes of 2023 which severely reduced the number of movies being released theatrically in the early months of 2024.Still, Chairman and CEO Adam Aaron said the firm remains confident that industry-wide movie revenues for the second half of 2024, and into 2025 and 2026 will continue to show increasing strength. “This in turn suggests that AMC should enjoy increasing adjusted earnings before interest, tax, depreciation, and amortization (EBITDA), if and when overall industry revenues are climbing,” he said.The firm is scheduled to report its full results for the second quarter after the market closes on August 2. Retail investors will be awaiting an update on whether the company plans to issue new equity capital to service its large debt loan, which it recently restructured by using its theaters as collateral.The stock hasn’t had a good year so far, having lost over 23% and remaining volatile as part of a core group of “meme stocks” tied to the influence of Roaring Kitty and others. On Wall Street, Macquarie recently raised its price target on the stock from $3.50 to $4.00 while giving an “Underperform” rating suggesting an improving, but still concerning picture.While a trading halt near the market-open allowed Stocktwits users to digest the news, many expressed concern about downside volatility ahead. Meanwhile, one user with a bearish stance on the stock is expecting it to eventually fall back below the $3 mark towards its all-time lows set in April.<figure class="image"><a href="https://stocktwits.com/_RickWithASilentP/message/580572369"><img style="aspect-ratio:789/146;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_24_at_1_33_12_PM_66083540ef.png" alt="Stocktwits user _RickWithASilentP's post on AMC Entertainment" width="789" height="146"></a><figcaption>Stocktwits user _RickWithASilentP's post on AMC Entertainment</figcaption></figure>

Retail Investors Hammer AMC Entertainment After It Discloses Preliminary Q2 Earnings: Here’s What The Firm Said

The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion while net loss is expected to be approximately $320.80 million, compared to net earnings of $8.60 million for the same period last year. 

The company expects a 23.50% year-over-year (YoY) fall in its revenue at $1.03 billion while net loss is expected to be approximately $320.80 million, compared to net earnings of $8.60 million for the same period last year. Retail remains concerned about further dilution given the company’s continued lack of profitability.

SFYF
SoFi Social 50 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SFYF News

SFYFSoFi Social 50 ETF